GlassScriptPhysician profile
Roy H Phillips
NPI 1881699411
$208,454.68
in general payments reported to CMS, 2019-2025
48 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $37K · 2021: $23K · 2022: $23K · 2023: $27K · 2024: $6,798 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $7,400 · Travel and Lodging: $2,470 · Consulting Fee: $450 · Education: $64.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,143.75 |
| Food and Beverage | $7,399.73 |
| Travel and Lodging | $2,470.32 |
| Consulting Fee | $450.00 |
| Education | $64.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106,962.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $36,728.95 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $27,551.41 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,389.08 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $8,625.59 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $5,042.26 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $497.16 | 2019-2025 | |
| Amarin Pharma, INC. | $488.27 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $430.88 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $425.12 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $304.58 | 2020-2025 | Gvoke Hypopen |
| Insulet Corporation | $300.24 | 2019-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $280.25 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $275.36 | 2019-2024 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $260.72 | 2021-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $228.34 | 2020-2025 | Tymlos |
| Cequr Corporation | $212.11 | 2023-2025 | Cequr Simplicity |
| Dexcom, INC. | $188.50 | 2019-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $162.61 | 2022-2025 | Strensiq |
| Lifescan, INC. | $153.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $148.92 | 2019-2020 | |
| Madrigal Pharmaceuticals | $147.78 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $141.32 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $137.55 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $129.92 | 2020-2022 | |
| Almatica Pharma LLC | $115.37 | 2024-2025 | Teriparatide, Loreev Xr |
| Beta Bionics, INC. | $113.14 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Horizon Therapeutics Plc | $110.32 | 2019-2023 | Tepezza |
| Neurocrine Biosciences, INC. | $97.74 | 2024-2025 | |
| Becton, Dickinson and Company | $71.59 | 2019-2022 | |
| Nevro Corp. | $67.91 | 2022 | |
| Medtronic, INC. | $67.18 | 2023-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $58.72 | 2019-2020 | |
| Antares Pharma, INC. | $56.48 | 2019-2024 | Xyosted |
| Pfizer INC. | $56.23 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $52.38 | 2023 | Isturisa, Signifor Lar |
| Valeritas, INC. | $51.57 | 2019 | |
| Embecta Corp. | $47.10 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amryt Pharma Holdings LTD | $39.15 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $37.40 | 2019-2020 | |
| Sequel Med Tech, LLC | $34.33 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $30.97 | 2019-2023 | |
| Averitas Pharma INC. | $30.92 | 2025 | Qutenza |
| Ibsa Pharma INC. | $28.35 | 2021-2022 | |
| Roche Diabetes Care, INC. | $28.00 | 2019 | |
| Ascendis Pharma Endocrinology INC | $19.56 | 2025 | Yorvipath |
| Shire North American Group INC | $15.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.